Experts explore the intricacies of managing brain metastases in HER2+ breast cancer and delve into the latest evidence, patient considerations, and evolving guidelines for this complex scenario.
Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.
Kristen Peterson, PharmD, BCOP, reviews pharmacists’ pivotal role in optimizing patient transitions between inpatient and outpatient care settings to ensure treatment continuity and medication management in multiple myeloma care.